Comparative Pharmacology
Head-to-head clinical analysis: NEMBUTAL versus SODIUM BUTABARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEMBUTAL versus SODIUM BUTABARBITAL.
NEMBUTAL vs SODIUM BUTABARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization. At high doses, has direct inhibitory effects on excitatory AMPA and kainate receptors.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing CNS depression.
Induction of anesthesia: 50-120 mg IV as a single dose. Maintenance of anesthesia: additional doses of 20-40 mg IV as needed. For sedation (preoperative): 100-200 mg IM or 1-5 mg/kg IV 1-1.5 hours before procedure. For status epilepticus: loading dose of 5-15 mg/kg IV slow push, then 1-5 mg/kg/h IV infusion.
50-100 mg orally or intramuscularly 3-4 times daily as a sedative; 100-200 mg orally or intramuscularly for preoperative sedation.
None Documented
None Documented
Terminal elimination half-life is 40-120 hours (mean ~80 hours). The prolonged half-life contributes to accumulation with repeated dosing and residual sedation.
Terminal elimination half-life 40-60 hours in adults; prolonged in hepatic impairment and elderly.
Renal elimination of unchanged drug accounts for approximately 30-35% of a dose; the remainder is hepatically metabolized. Less than 5% is excreted unchanged in feces.
Renal excretion of unchanged drug and metabolites; approximately 30-50% as unchanged drug in urine. Minor fecal elimination (<5%).
Category C
Category C
Barbiturate
Barbiturate